LCLennart Conemans

Lennart Conemans

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lennart Conemans has a total of 100 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    T2 Inflammatory Profile in Relation to Lung Function Impairment in the General Population

    by Charmaine J. M. Lim, Lennart Conemans, Tobias L. Mraz, David A. Kaminsky, Charles G. Irvin, Marie‐Kathrin Breyer, Michael Sturm, Mohammad Azizzadeh, Ahmad Karimi, Frits M. E. Franssen, et al.

    Summary: T2 biomarkers showed respiratory physiology‐specific associations, particularly with airflow limitation, peripheral airway dysfunction, and air trapping. Combined eosinophils and FeNO elevation identified greater physiological impairment than individual biomarkers alone.

  • Type 2 status is associated with longitudinal worsening of airway function assessed by oscillometry in a population-based cohort

    by Lennart Conemans, Charmaine Lim, Charles Irvin, David Kaminsky, Pasquale Pompilio, Marie-Kathrin Breyer, Frits Franssen, Emiel Wouters, Robab Breyer-Kohonsal

    Background: Type 2 (T2) status is associated with asthma and lung function decline, but its longitudinal impact on airway function measured by oscillometry has not been examined. Aims and objectives: To assess whether T2 status is associated with longitudinal changes in oscillometry in a population-based cohort, and whether this is modified by asthma. Methods: Adults in the population-based LEAD cohort with follow-up data were included (n=892; asthma n=83; mean follow-up 4.3 years (SD ± 0.21)). T2-high was defined as blood eosinophils ≥300 cells/µL and FeNO ≥25 ppb. For asthma effect modification, T2-int/high (eosinophils ≥300 and/or FeNO ≥25) was used to increase power. Follow-up minus baseline change in oscillometry (R, X, and Z [combined resistance and reactance]) at 5 Hz, R5-19) and FEV1 was analysed as z-scores using adjusted linear regression (weight, smoking status, pack-years), including a T2 x asthma interaction. Results: Compared with T2-low, baseline T2-high was associated with change in R5 (β=0.28, 95% CI 0.03–0.52, p=0.027), Z (β=0.26, 95% CI 0.01–0.51, p=0.043) and FEV1 (β=0.22, 95% CI 0.03–0.41, p=0.022), with no significant associations for R5-R19 or X5. Using T2-int/high, asthma modified these associations, with greater T2-related change for R5 (β=0.45, 95% CI 0.03–0.87, p=0.034) and Z (β=0.55, 95% CI 0.13–0.98, p=0.011); effect modification was not significant for FEV1 (β=-0.30, 95% CI -0.62–0.02, p=0.064), R5-R19, or X5. Conclusions: In this population-based study, T2 status is associated with longitudinal changes of oscillometric parameters, particularly in R and Z, with stronger effects in the presence of asthma, possibly reflecting overall airway narrowing. Our data support the complementary value of oscillometry in longitudinal follow-up of T2 asthmatics.

  • Open Access

    Attitudes and Practices Regarding Dosing Interval Extension of Biologics in Severe Asthma: A Nationwide Survey and Real-World Data From the Dutch RAPSODI Registry

    by Camiel J.M. Marijnissen, Jacob K. Sont, Fleur L. Meulmeester, Michel W.J.M. Wouters, Gert-Jan Braunstahl, Arnoud F. Aldenkamp, Simone Hashimoto, Johannes A. Kroes, M. Elske van Den Akker-Van Marle, Ewout W. Steyerberg, et al.

  • Open Access

    Functional respiratory imaging reveals early structural and functional airway responses to benralizumab in severe eosinophilic asthma

    by Lennart Conemans, Qichen Deng, Sami O Simons, Frits M E Franssen, Martijn A Spruit, Bita Hajian

    Background: Benralizumab improves outcomes in severe eosinophilic asthma (SEA). We aimed to evaluate early effects of benralizumab on airway pathophysiology using functional respiratory imaging (FRI). Methods: In this prospective, single-arm study, 20 adults with SEA underwent CT at baseline, 4 and 12 weeks. Coprimary endpoints were changes in specific airway volume (siVaw) and resistance (siRaw) at functional residual capacity (FRC) and total lung capacity (TLC) at 12 weeks. Imaging outcomes included mucus score/volume and air-trapping. Results: At week 12, siVaw increased at FRC by 0.16 mL/L (27%; 95% CI 0.01% to 0.31%; p = 0.02) and at TLC by 0.14 mL/L (14%; 95% CI 0.03% to 0.25%; p = 0.02); siRaw at TLC decreased by −0.41 kPa·s/L (−24%; 95% CI −0.80% to −0.01%; p = 0.04). siRaw at FRC increased (2.99 kPa·s/L; 95% CI −4.57 to 10.54; p=0.42), with a significant relative change (293%; p=0.03) that lost significance after excluding outliers. siVaw at FRC increased early (week 4: 0.19 mL/L; 33%; 95% CI 0.03% to 0.34%; p = 0.01). At week 12, the mucus score decreased by 0.41 (95% CI −0.67 to −0.14; p<0.01), and air-trapping by 5.5% (95% CI −8.8 to −2.1; p < 0.01). Changes in siVaw and mucus correlated with improvements in forced expiratory volume in 1 s (r = 0.66 and −0.77; both p<0.01) and Saint George’s Respiratory Questionnaire (mucus: r = 0.45; p = 0.05). Conclusions: Benralizumab treatment in SEA was associated with early improvements in airway volume, resistance, mucus and air-trapping, correlating with better lung function and quality of life. These findings support FRI to monitor early treatment effects. Trial registration number: NL-OMON26915.

  • Open Access

    Impact of Dupilumab for Severe Asthma on Fatigue, Quality of Life, Work Productivity, and Activity

    by Lianne Ten Have, Karin B. Fieten, Fleur.L. Meulmeester, Els J.M. Weersink, Pieter-Paul Hekking, Sarah A. van Nederveen-Bendien, Arnoud F. Aldenkamp, Kornelis W. Patberg, Marjo J.T. van de Ven, Ilonka H. van Veen, et al.


  • Open Access

    Out of Breath, out of Options: Benralizumab as a Last Hope in ICU‐Treated Near‐Fatal Eosinophilic Asthma: A Case Series

    by Lennart Conemans, Emel Demir, Martijn Bischoff, Frits Franssen, Sami Simons

    Asthma exacerbations remain life‐threatening events despite advancements in biologic therapies. This case series reports on four patients with near‐fatal eosinophilic asthma exacerbations who had been admitted to intensive care and were treated with benralizumab as a last resort after failing maximal standard therapies. All patients exhibited marked blood or airway eosinophilia and required intensive care ventilatory support. Following the administration of benralizumab, significant clinical improvements were observed. This series highlights the potential role of benralizumab in treating life‐threatening asthma exacerbations driven by eosinophilic airway inflammation and underlines the need for phenotyping and timely intervention in managing such patients with near‐fatal asthma while also stressing the need for continued adherence to asthma guidelines to prevent these extreme situations.


  • Open Access

    The Long-Term Uptake of Home Spirometry in Regular Cystic Fibrosis Care: Retrospective Multicenter Observational Study

    by Pia Bertram, Martinus C Oppelaar, Michiel Age Bannier, Monique He Reijers, Hester van der Vaart, Renske van der Meer, Josje Altenburg, Lennart Conemans, Bart L Rottier, Marianne Nuijsink, et al.

    Background: Home spirometers have been widely implemented in the treatment of people with cystic fibrosis (CF). Frequent spirometry measurements at home could lead to earlier detection of exacerbations. However, previous research indicates that the long-term use of home spirometry is not well maintained by people with CF. Objective: We aimed to gain insight into the long-term uptake of home spirometry in regular multicenter CF care. Methods: Home spirometers combined with a remote monitoring platform were introduced in the treatment of people with CF in 5 Dutch CF centers starting in April 2020. Usage data from April 2020 to December 2022 were analyzed retrospectively. Survival analyses were conducted to assess use consistency over time, and t tests were used to evaluate the impact of increased pulmonary symptoms on home spirometry frequency. The effect of the initiation of a new treatment, Elexacaftor/Tezacaftor/Ivacaftor, on use frequency over time was assessed in a subgroup of participants with repeated measures ANOVA. Results: During the observation period, a total of 604 people with CF were enrolled in the remote monitoring platform and 9930 home spirometry measurements were performed. After the initiation of home spirometry use, the number of users declined rapidly. One year after the initiation, 232 (54.2%) people with CF stopped using home spirometry. During the observation period, 67 (11.1%) users performed more than 20 measurements. Furthermore, the number of consistent home spirometry users decreased over time. After 600 days, only 1% of users had measured their lung function consistently every 31 days. Use frequency slightly increased during periods with increased pulmonary symptoms (ΔMean=0.45, t497.278=–4,197; P<.001) and showed an initial rise followed by a decrease after starting treatment with Elexacaftor/Tezacaftor/Ivacaftor (ΔMean=0.45, t497.278=–4,197; P<.001). Conclusions: Consistent uptake of home spirometry in people with CF is low but increases around periods of changing symptoms. A clear strategy for the organization of remote care seemed to improve the long-term uptake of home spirometry. Nevertheless, home spirometry and its intensity are not a goal on their own but should be used as a tool to reach individual goals within local contexts.


  • Open Access

    Accuracy, Reproducibility, and Responsiveness to Treatment of Home Spirometry in Cystic Fibrosis: Multicenter, Retrospective, Observational Study

    by Martinus C Oppelaar, Hanneke Ac van Helvoort, Michiel Age Bannier, Monique He Reijers, Hester van der Vaart, Renske van der Meer, Josje Altenburg, Lennart Conemans, Bart L Rottier, Marianne Nuijsink, et al.

    Background: Portable spirometers are increasingly used to measure lung function at home, but doubts about the accuracy of these devices persist. These doubts stand in the way of the digital transition of chronic respiratory disease care, hence there is a need to address the accuracy of home spirometry in routine care across multiple settings and ages. Objective: This study aimed to assess the accuracy, reproducibility, and responsiveness to the treatment of home spirometry in long-term pediatric and adult cystic fibrosis care. Methods: This retrospective observational study was carried out in 5 Dutch cystic fibrosis centers. Home spirometry outcomes (forced expiratory volume in one second [FEV1], and forced vital capacity [FVC]) for 601 anonymized users were collected during 3 years. For 81 users, data on clinic spirometry and elexacaftor/tezacaftor/ivacaftor (ETI) use were available. Accuracy was assessed using Bland-Altman plots for paired clinic-home measurements on the same day and within 7 days of each other (nearest neighbor). Intratest reproducibility was assessed using the American Thoracic Society/European Respiratory Society repeatability criteria, the coefficient of variation, and spirometry quality grades. Responsiveness was measured by the percentage change in home spirometry outcomes after the start of ETI. Results: Bland-Altman analysis was performed for 86 same-day clinic-home spirometry pairs and for 263 nearest neighbor clinic-home spirometry pairs (n=81). For both sets and for both FEV1 and FVC, no heteroscedasticity was present and hence the mean bias was expressed as an absolute value. Overall, home spirometry was significantly lower than clinic spirometry (mean ΔFEV1clinic-home 0.13 L, 95% CI 0.10 to 0.19; mean ΔFVCclinic-home 0.20 L, 95% CI 0.14 to 0.25) and remained lower than clinic spirometry independent of age and experience. One-way ANOVA with post hoc comparisons showed significantly lower differences in clinic-home spirometry in adults than in children (Δmean 0.11, 95% CI –0.20 to –0.01) and teenagers (Δmean 0.14, 95% CI –0.25 to –0.02). For reproducibility analyses, 2669 unique measurement days of 311 individuals were included. Overall, 87.3% (2331/2669) of FEV1 measurements and 74.3% (1985/2669) of FVC measurements met reproducibility criteria. Kruskal-Wallis with pairwise comparison demonstrated that for both FVC and FEV1, coefficient of variation was significantly lower in adults than in children and teenagers. A total of 5104 unique home measurements were graded. Grade E was given to 2435 tests as only one home measurement was performed. Of the remaining 2669 tests, 43.8% (1168/2669) and 43.6% (1163/2669) received grade A and B, respectively. The median percentage change in FEV1 from baseline after initiation of ETI was 19.2% after 7-14 days and remained stable thereafter (n=33). Conclusions: Home spirometry is feasible but not equal to clinic spirometry. Home spirometry can confirm whether lung functions remain stable, but the context of measurement and personal trends are more relevant than absolute outcomes.


  • Effect of benralizumab on airway mucus, air-trapping and airway volume, assessed by functional respiratory imaging in severe eosinophilic asthma

    by Lennart Conemans, Miriam Groenen, Sami Simons, Martijn Spruit, Bita Hajian

    Introduction: Severe eosinophilic asthma (SEA) responds favorably to benralizumab, owing to its anti-eosinophilic effects. However, its influence on airway physiology is less well understood. Using Functional Respiratory Imaging (FRI), this study explored benralizumab's short-term effects on airway pathology in SEA. Methods: A single-arm trial involving 20 SEA patients that started benralizumab, with HRCT scans at FRC and TLC at baseline, 4, and 12 weeks, was performed. FRI-based outcomes included mucus score (MS), air-trapping (AT) and airway volume (SIVAW). Spirometry, oscillometry, bodyplethysmography, FeNO, ACQ and SGRQ were other outcome parameters. Data were analyzed using linear mixed models. Results: Significant (p<0.05) LSM differences in MS (−0.52 point) and AT (−5.5 points) were observed at week 12 (figure shows an individual response). An inverse relationship between MS and FEV1 was observed, where each MS point decrease resulted in a 1.33% increase in FEV1. Significant improvements in SIVAW were noted by week 12 at TLC (+14%) and FRC (+27%). Conclusion: Benralizumab decreases airway mucus, increases airway volume and reduces air-trapping in SEA, as shown by FRI. FRI visualizes the capability of benralizumab to modify mucus plugging in the short-term. This could support selection and monitoring of biologic therapies for SEA. erj;64/suppl_68/PA5367/F1 F1 F1


  • Open Access

    Potential, Pitfalls, and Future Directions for Remote Monitoring of Chronic Respiratory Diseases: Multicenter Mixed Methods Study in Routine Cystic Fibrosis Care

    by Martinus C Oppelaar, Yvette Emond, Michiel A G E Bannier, Monique H E Reijers, Hester van der Vaart, Renske van der Meer, Josje Altenburg, Lennart Conemans, Bart L Rottier, Marianne Nuijsink, et al.

    Background: The current literature inadequately addresses the extent to which remote monitoring should be integrated into care models for chronic respiratory diseases (CRDs). Objective: This study examined a remote monitoring program (RMP) in cystic fibrosis (CF) by exploring experiences, future perspectives, and use behavior over 3 years, with the aim of developing future directions for remote monitoring in CRDs. Methods: This was a mixed methods, multicenter, observational study in 5 Dutch CF centers following a sequential explanatory design. Self-designed questionnaires using the technology acceptance model were sent out to people with CF who had a minimum of 12 months of experience with the RMP and local health care professionals (HCPs). Questionnaire outcomes were used to inform semistructured interviews with HCPs and people with CF. Qualitative findings were reported following the COREQ (Consolidated Criteria for Reporting Qualitative Research) checklist. Anonymous data on use frequency of all people with CF were analyzed. Results: Between the second quarter of 2020 and the end of 2022, a total of 608 people with CF were enrolled in the program, and a total of 9418 lung function tests and 2631 symptom surveys were conducted. In total, 65% (24/37) of HCPs and 89% (72/81) of people with CF responded to the questionnaire, and 7 HCPs and 12 people with CF participated in semistructured interviews. Both people with CF and HCPs were positive about remote monitoring in CF care and found the RMP a good addition to daily care (people with CF: 44/72, 61%; HCPs: 21/24, 88%). Benefits ranged from supporting individual patients to reducing health care consumption. The most valued monitoring tool was home spirometry by both people with CF (66/72, 92%) and HCPs (22/24, 92%). Downsides included the potential to lose sight of patients and negative psychosocial effects, as 17% (12/72) of people with CF experienced some form of stress due to the RMP. A large majority of people with CF (59/72, 82%) and HCPs (22/24, 92%) wanted to keep using the RMP in future, with 79% (19/24) of HCPs and 75% (54/72) of people with CF looking forward to more replacement of in-person care with digital care during periods of well-being. Future perspectives for the RMP were centered on creating hybrid care models, personalizing remote care, and balancing individual benefits with monitoring burden. Conclusions: Remote monitoring has considerable potential in supporting people with CF and HCPs within the CF care model. We identified 4 practice-based future directions for remote monitoring in CF and CRD care. The strategies, ranging from patient driven to prediction driven, can help clinicians, researchers, and policy makers navigate the rapidly changing digital health field, integrate remote monitoring into local care models, and align remote care with patient and clinician needs.